Patentes

1.- WO2022152800A1 TETRAHYDRO-SPIROINDOLINE-PYRROLOPYRROLE-TRIONES INHIBITORS OF THE NRF2-BETA-TRCP INTERACTION FOR USE IN THE TREATMENT OF FATTY LIVER DISEASE

By: Cuadrado Pastor, Antonio; Fernandez Gines, Raquel; Encinar, Jose Antonio; Leon Martinez, Rafael; Franco Gonzalez, Juan Felipe; Garcia Lopez, Manuela; Rodriguez Franco, Maria Isabel; Rojo Sanchis, Ana Isabel

The present invention relates to NRF2-betaTrCP interaction inhibitors with general formula I and its derivate salts for use in the treatment of NRF2-related diseases caused by chronic inflammation and oxidative stress. More specifically the present invention relates to NRF2-betaTrCP interaction inhibitors with specific formula I and its derivate salts for treating diseases of the liver related with chronic inflammation and oxidative stress, such as fatty liver disease.

EUROPEAN PATENT APPLICATION
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

2.- WO2025104221A1 USES OF PROTEIN TYROSINE PHOSPHATASE RECEPTOR KAPPA INHIBITORS.

By: GURZOV, Esteban; GILGLIONI, Eduardo; ENCINAR, José Antonio
World Intellectual Property Organization, WO2025104221A1 EP2024082453W·2024-11-15 | Language: English

This application discloses Protein Tyrosine Phosphatase Receptor Kappa (PTPRK) inhibitors for use in medicine, in particular for use in the treatment and/or prevention of a condition selected from the group consisting of overweight, obesity, hyperglycaemia, diabetes, hyperlipidaemia, a non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma, and combinations thereof. Also disclosed is a pharmaceutical composition comprising a PTPRK inhibitor or a combination of PTPRK inhibitors for use in the treatment and/or prevention of a condition selected from the group consisting of overweight, obesity, hyperglycaemia, diabetes, hyperlipidaemia, a non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma, and combinations thereof.

3.- WO2026008907 COMPOUNDS IDENTIFIED AS CDK4 INHIBITORS FOR USE AS MEDICATIONS.

By: DE JUAN ROMERO, Camino, SACEDA SÁNCHEZ, Miguel, FUENTES BAILE, María, ARAUJO ABAD, Salomé, ENCINAR HIDALGO, José Antonio, GARCÍA MORALES, María Pilar, PÉREZ VALENCIANO, Elizabeth, FERNÁNDEZ ESCAMILLA, Ana María.

The invention relates to compounds that have been identified as CDK4 (cyclin-dependent kinase enzyme) inhibitors for the first time, for use as a medication, in particular, for the treatment of cancers e.g. those with overexpression of the enzyme CDK4, and to pharmaceutical compositions comprising same. Said compounds target the interaction interface between CDK4 and its activating cyclin, whereas those drugs already approved for the treatment of cancers with overexpression of the enzyme CDK4 target the ATP-binding site.

4.- En fase de redacción: Compuesto RM como (re)mielinizante y antigliomagénico.